RxDoctor Payments Data

Krista Pembroke, NP

Psychiatric/Mental Health · Virginia Beach, VANPI 1043920606

Payments from drug & device makers

$4,559in general payments, 2019–2025

Across 215 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$680
  • Axsome Therapeutics, Inc.$607
  • Johnson & Johnson$575
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$492
  • Alkermes, Inc.$408
  • Vanda Pharmaceuticals Inc.$238
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$4,559100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,559 in reported general payments places this provider in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$1,870
Medicare patients
11
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate13$20,121
AuvelityDextromethorphan Hbr/Bupropion12$11,038
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine37$1,103
Tranylcypromine Sulfate14$947
Aripiprazole15$838
Divalproex Sodium ErDivalproex Sodium11$548
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$520
Quetiapine Fumarate26$394
Risperidone14$391
Clonazepam40$304
Bupropion XlBupropion Hcl13$219
Trazodone Hcl47$191
Bupropion Hcl SrBupropion Hcl15$165
Escitalopram Oxalate27$163
Gabapentin12$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$492$20,12113 claims
Axsome Therapeutics, Inc.Auvelity$607$11,03812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →